DK1583538T3 - Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme - Google Patents

Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme

Info

Publication number
DK1583538T3
DK1583538T3 DK04702722T DK04702722T DK1583538T3 DK 1583538 T3 DK1583538 T3 DK 1583538T3 DK 04702722 T DK04702722 T DK 04702722T DK 04702722 T DK04702722 T DK 04702722T DK 1583538 T3 DK1583538 T3 DK 1583538T3
Authority
DK
Denmark
Prior art keywords
alpha
pregnenolone
medicament
methozy
manufacture
Prior art date
Application number
DK04702722T
Other languages
English (en)
Inventor
Etienne-Emile Baulieu
Esther Fellous
Paul Robel
Original Assignee
Mapreg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapreg filed Critical Mapreg
Application granted granted Critical
Publication of DK1583538T3 publication Critical patent/DK1583538T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK04702722T 2003-01-17 2004-01-16 Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme DK1583538T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0300507A FR2850023B1 (fr) 2003-01-17 2003-01-17 Medicaments pour le systeme nerveux
PCT/FR2004/000086 WO2004067010A1 (fr) 2003-01-17 2004-01-16 Utilisation de la 3-methoxy-pregnenolone pour la preparation d’un medicament destine a traiter les maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
DK1583538T3 true DK1583538T3 (da) 2008-12-01

Family

ID=32605831

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04702722T DK1583538T3 (da) 2003-01-17 2004-01-16 Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme

Country Status (9)

Country Link
US (3) US8034798B2 (da)
EP (1) EP1583538B1 (da)
AT (1) ATE402710T1 (da)
DE (1) DE602004015406D1 (da)
DK (1) DK1583538T3 (da)
ES (1) ES2311790T3 (da)
FR (1) FR2850023B1 (da)
PT (1) PT1583538E (da)
WO (1) WO2004067010A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850023B1 (fr) * 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
CA2680119A1 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Steroids derivatives as selective progesterone receptor modulators
HUE031390T2 (en) * 2011-05-20 2017-07-28 Inserm - Inst Nat De La Sante Et De La Rech Medicale CB1 receptor antagonists
RU2665571C2 (ru) * 2011-09-08 2018-08-31 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, композиции и их применения
NZ708086A (en) * 2012-11-28 2020-04-24 Inst Nat Sante Rech Med 3-(4’-substituted)-benzyl-ether derivatives of pregnenolone
RS58166B1 (sr) 2013-03-13 2019-03-29 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
CN113501855A (zh) 2015-07-06 2021-10-15 萨奇治疗股份有限公司 氧甾醇及其使用方法
RU2744267C2 (ru) 2015-07-06 2021-03-04 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3165225A1 (en) 2015-11-06 2017-05-10 Mapreg Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of substance use disorders
EP3436024A1 (en) 2016-03-01 2019-02-06 Mapreg Non-bioconvertible c3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression
US9943528B2 (en) 2016-03-01 2018-04-17 Mapreg Non-bioconvertible C3-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression
PT3436022T (pt) 2016-04-01 2022-07-04 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA45598B1 (fr) 2016-07-07 2021-09-30 Sage Therapeutics Inc Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
AU2017337121B2 (en) 2016-09-30 2022-01-27 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as NMDA modulators
EP4105223A1 (en) 2016-10-18 2022-12-21 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
IL266093B2 (en) 2016-10-18 2024-02-01 Sage Therapeutics Inc Oxysterols and methods of using them

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
EP0840612A1 (en) * 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
FR2806303B1 (fr) * 2000-03-17 2002-09-27 Inst Nat Sante Rech Med Composes capables de se lier a des proteines constituantes ou associees aux elements du cytosquelette et leurs applications pour la fabrication de medicaments
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
AU2002217841A1 (en) * 2000-11-06 2002-05-15 Trustees Of Boston University Neuroactive steroid derivatives and methods of use
EP1310258A1 (en) * 2001-11-08 2003-05-14 Etienne-Emile Baulieu Enantiomers of steroids for the enhancement of memory and cognitive function
FR2850023B1 (fr) * 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
US9339508B2 (en) * 2003-01-17 2016-05-17 Mapreg Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury

Also Published As

Publication number Publication date
FR2850023A1 (fr) 2004-07-23
EP1583538B1 (fr) 2008-07-30
WO2004067010A1 (fr) 2004-08-12
ATE402710T1 (de) 2008-08-15
EP1583538A1 (fr) 2005-10-12
US20160166586A1 (en) 2016-06-16
US8334278B2 (en) 2012-12-18
US20060199790A1 (en) 2006-09-07
ES2311790T3 (es) 2009-02-16
US10561671B2 (en) 2020-02-18
US20090143347A1 (en) 2009-06-04
PT1583538E (pt) 2008-10-30
DE602004015406D1 (de) 2008-09-11
FR2850023B1 (fr) 2007-04-06
US8034798B2 (en) 2011-10-11

Similar Documents

Publication Publication Date Title
DK1583538T3 (da) Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
IS8230A (is) Setið 2-amínótetralín til notkunar við meðferð á þunglyndi
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE60315492D1 (de) Medizinisch verwendbare arylethanolamin verbindungen
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
BR0315580A (pt) Derivados de metileno uréia
CY1109045T1 (el) Ρετινοειδη για τη θεραπεια του εμφυσηματος
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
UA90504C2 (ru) Лекарственное средство для лечения заболеваний дыхательных путей
MXPA05010020A (es) Derivados de oxamida.
MXPA05005790A (es) Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central.
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
DE60215313D1 (de) Indolderivate und deren verwendung als gnrh antagonisten
DK1511496T3 (da) Fremgangsmåde til behandling eller forebyggelse af immunmedierede sygdomme og farmaceutisk præparat til anvendelse heri
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments